Pulmonx Corporation
LUNG · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | -0.51 | 0.60 | 0.75 |
| FCF Yield | -3.80% | -5.03% | -2.58% | -2.35% |
| EV / EBITDA | -6.15 | -17.26 | -13.28 | -25.08 |
| Quality | ||||
| ROIC | -11.79% | -10.91% | -10.66% | -9.52% |
| Gross Margin | 72.11% | 72.51% | 74.44% | 73.70% |
| Cash Conversion Ratio | 0.58 | 0.26 | 0.92 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.24% | 14.29% | 15.07% | 16.01% |
| Free Cash Flow Growth | 70.74% | -97.68% | 10.67% | -22.74% |
| Safety | ||||
| Net Debt / EBITDA | 1.34 | 1.21 | 0.76 | 0.59 |
| Interest Coverage | -18.53 | -18.65 | -17.97 | -15.86 |
| Efficiency | ||||
| Inventory Turnover | 0.41 | 0.37 | 0.36 | 0.32 |
| Cash Conversion Cycle | 190.06 | 237.80 | 246.12 | 262.29 |